Vita Life SciencesASX:VLS 94 ROE % is 20.54% as of Dec. 2025, which is 9% above its 10-year median of 18.79. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 936 Drug Manufacturers companies, Vita Life Sciences ranks better than 86.97% on this metric.
The historical rank and industry rank for Vita Life Sciences's ROE % or its related term are showing as below:
ASX:VLS'
s ROE % Range Over the Past 10 Years
Min: 10.35 Med: 18.79 Max: 29.9
Current: 19.41
During the past 13 years, Vita Life Sciences's highest ROE % was 29.90%. The lowest was 10.35%. And the median was 18.79%.
ASX:VLS's ROE % is ranked better than 86.97% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs ASX:VLS: 19.41
Vita Life Sciences (ASX:VLS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Vita Life Sciences ROE % Related Terms
Vita Life Sciences ROE % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's ROE % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Vita Life Sciences (ASX:VLS) has a ROE % of 20.54% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 18.79. Over the past decade, Vita Life Sciences' ROE % has ranged from 10.35 to 29.90. According to the industry distribution chart, Vita Life Sciences ranks #122 out of 936 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Vita Life Sciences' ROE % too high?
Vita Life Sciences' current ROE % of 20.54% is near median its 10-year median of 18.79. Over the past 10 years, this metric has ranged from a low of 10.35 to a high of 29.90. The Drug Manufacturers industry median ROE % is 5.87. Vita Life Sciences' value of 20.54% is 250.2% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #122 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #122 out of 936 companies for ROE %. This places Vita Life Sciences in the top 13% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Vita Life Sciences' value of 20.54% is 250.2% above this benchmark. Historically, Vita Life Sciences' own ROE % has ranged from 10.35 to 29.90 over the past decade. While the company's 10-year median is 18.79 vs. the industry median of 5.87, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current ROE % of 20.54% is 250.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current ROE % is 20.54%, which is near median its own 10-year median of 18.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current ROE % is 20.54%, which is near median its 10-year median of 18.79 and 250.2% above the Drug Manufacturers industry median of 5.87. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current ROE % is 20.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
ROE %: 20.54% (near median its 10-year median of 18.79)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 250.2% above the Drug Manufacturers median (#122 of 936)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
